Specify a stock or a cryptocurrency in the search bar to get a summary
OUTLOOK THERAPEUTICS INC
OTLKOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. Address: Building F, Iselin, NJ, United States, 08852
Analytics
WallStreet Target Price
39.23 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures OTLK
Dividend Analytics OTLK
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History OTLK
Stock Valuation OTLK
Financials OTLK
Results | 2019 | Dynamics |